Hims(HIMS) The Motley Fool·2025-02-21 19:37Core Insights - Hims & Hers Health's stock has experienced a significant decline, losing 23.2% as of 1 p.m. ET, with a peak drop of 26.1% earlier in the day, coinciding with broader market losses [1] - The company is facing a potential loss of a key revenue source due to the FDA's decision to remove semaglutide injection products from its shortage list, which previously allowed Hims & Hers to sell compounded versions [2][3] Company Impact - The FDA's action against "compounders" will limit the availability of semaglutide products to only brand-name versions, leading to a marked reduction in revenue for Hims & Hers [2][3] - Despite the negative news, the CEO of Hims & Hers remains optimistic about the potential for other personalized weight loss products that can be offered through a newly acquired peptide facility [4]